Regulated Information -

Financial Reports

Mar
2022

Annual Report 2021

Mar
2022

Full Year 2021 Annual Report & Business Highlights

May
2022

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Mar
2021

Full Year 2020 Annual Report & Business Highlights

Mar
2021

Annual Report 2020

May
2021

First Quarter 2021 Financial Results and Recent Business Highlights

Aug
2021

Half Year 2021 Financial Results & Business Highlights

Nov
2021

Third Quarter 2021 Financial Results and Recent Business Highlights

Mar
2020

Full Year 2019 Annual Report

Apr
2020

Annual Report 2019

May
2020

First Quarter 2020 Financial Results and Recent Business Highlights

Aug
2020

Half Year 2020 Financial Results and Business Highlights

Nov
2020

Third Quarter 2020 Financial Results and Recent Business Highlights

Mar
2019

Full Year 2018 Financial and Operating Results

Apr
2019

Annual Report 2018

May
2019

First Quarter 2019 Financial Results and Recent Business Highlights

Aug
2019

Interim Financial Report H1.2019

Nov
2019

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Mar
2018

Full year 2017 Financial and Operating Results

Apr
2018

Annual report 2017

May
2018

First Quarter 2018 Financial Results and Recent Business Highlights

Aug
2018

First Half 2018 Financial Results and Operational Progress

Nov
2018

Third Quarter 2018 Business Update

Mar
2017

Celyad Reports 2016 Financial and Operating Results

May
2017

First Quarter 2017 Business Update

May
2017

Celyad’s Annual Report 2016

Aug
2017

First Half 2017 Financial statements and operational progress

Apr
2016

AR 2015 Annual report

May
2016

Q1 2016 Business Update

Aug
2016

Celyad 2016 First Half Year Report

Nov
2016

Q3 2016 Business Update

Jun
2015

H1 2015 Interim Financial Report

Nov
2015

Q3 2015 Business Update

SEC Filings

Filter

Filing Date

Form

Description

Filing Group

Downloads

January 12, 2022

6-K

Celyad Oncology Provides Outlook For 2022

December 14, 2021

6-K

Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

December 8, 2021

6-K

Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate

December 3, 2021

6-K

Celyad Oncology Announces $32.5 Million Private Placement With Fortress Investment Group

November 12, 2021

6-K

Celyad Oncology Presents Preclinical Data On Allogeneic CAR T Therapy Program And Highlights KEYNOTE-B79 Clinical Trial Design At The Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting

November 10, 2021

6-K

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights